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OBJECTIVES: Novel combination therapies can improve survival compared with 
chemotherapy alone in patients with advanced NSCLC. However, acceptable tolera-         
bility is also important as it affects clinical outcomes, quality of life, and overall cancer 
treatment costs. This analysis assesses direct medical costs for the management of 
grade 3/4 adverse events (AEs) associated with two non-chemotherapies for ﬁrst-line 
treatment of NSCLC consisting of either Bevacizumab (BEV) plus chemotherapy (CT) 
or Cetuximab (C) plus cisplatin/vinorelbine (CV). METHODS: Information on AE 
proﬁles were retrieved from the AVAiL study (7.5 mg/kg, Reck et al. 2009) and the        
E4599 study (15 mg/kg, Sandler et al. 2006) for BEV       CT and from the FLEX study 
(Pirker et al. 2009) for CCV. To account for the inclusion of ECOG 2 patients in 
FLEX (which were excluded in AVAiL and E4599), incidences of febrile neutropenia, 
non-febrile neutropenia and leukopenia in FLEX were decreased by up to 30% based 
on expert suggestion to improve study comparability. Information on standard treat-
ment patterns of the different AEs was collected through a systematic literature search 
and complemented by data provided by two German oncologists. These resource use 
items were assigned unit costs (charges) applicable to Germany. RESULTS: When 
unadjusted incidences of all AEs reported in AVAiL, E4599, and FLEX are used, 
resulting overall per-patient treatment costs related to the two BEVCT studies are 
substantially lower those related to CCV (a1092 and a464 versus a2287). Sensitivity 
analyses provide evidence that overall AE costs remain lower for AVAiL and E4599 
even when incidences for selected AEs affected by cetuximab therapy are reduced by 
10%, 20%, and 30% (a2151, a2015, and a1879, respectively). CONCLUSIONS: 
BEVCT shows better tolerability linked with lower AE treatment costs when com-
pared to CCV. These favorable outcomes for BEVCT were maintained when AE 
frequencies for CCV were adjusted for ECOG status.
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OBJECTIVES: Novel combination therapies can improve survival as compared to         
chemotherapy alone in patients with advanced NSCLC. Essential is also that these          
new therapies have acceptable tolerability proﬁles. Furthermore, toxicities can result 
in potentially high additional treatment costs. This analysis therefore aims to explore 
overall costs of adverse events (AEs) associated with two new biologics in ﬁrst-line 
NSCLC consisting of either Bevacizumab (BEV) combined with chemotherapy (CT) 
or Cetuximab (C) combined with cisplatin  vinorelbine (CV). METHODS: All pub-
lished AEs and their incidences as reported in the AVAiL study (7.5 mg/kg, Reck et    
al. 2009) and the E4599 study (15 mg/kg, Sandler et al. 2006) were considered for         
BEVCT, whereas AE data for CCV was taken from the FLEX study (Pirker et al. 
2009). A systematic literature search was performed to collect published information 
on standard treatment patterns and costs of AEs. To complement and further sub-
stantiate these results, two oncologists in Germany were interviewed to obtain 
 additional information on medical resource utilization for the AEs considered. These 
resource use items were then assigned unit costs (charges) reﬂective of the German 
health care system. A spreadsheet model was used to calculate total average per-patient 
AE costs for the two compared therapy regimens. RESULTS: Our analysis shows 
substantially lower overall per-patient treatment costs for the grade 3/4 AE proﬁles 
speciﬁed in both BEV NSCLC trials (AVAiL and E4599) than for all severe AEs 
observed in the FLEX trial (a1092 and a464 versus a2287). The differences favouring 
BEVCT are mainly due to lower incidences of febrile neutropenia, leukopenia, neu-
tropenia, sepsis, and anaemia than observed for a CCV regimen. CONCLUSIONS: 
BEVCT shows better tolerability and lower AE treatment costs as compared to 
CCV. Coupled with its favorable effectiveness, BEVCT should be considered as 
therapy of choice for patients with advanced NSCLC.
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OBJECTIVES: To estimate the average lifetime cost of care for patients with colorectal 
cancer in Ireland, from the perspective of the health care payer (HSE). METHODS: 
A decision tree model was developed in Microsoft Excel. Treatment pathways were 
constructed for each stage of colon cancer (CC) and rectal cancer (RC) from guidelines 
and expert clinical opinion. Healthcare resource use associated with diagnosis, treat-
ment and follow-up were obtained from the National Cancer Registry (n  1,498; 
36% RC and 64% CC; 2004–2005), and two local hospital databases (n  155 and 
142; 2007). Unit costs for hospitalisation, procedures, laboratory tests and radiother-
apy were derived from DRG costs, hospital ﬁnance departments, clinical opinion and 
literature review. Chemotherapy costs were estimated from local hospital protocols, 
pharmacy department and clinical opinion. Future costs of follow-up were discounted 
at 4% over 5 years. Uncertainty was explored using one-way sensitivity analysis. 
RESULTS: Average lifetime costs per patient were higher for RC (Stage I a24,089; 
Stage II a40,950; Stage III a49,987; Stage IV a45,237) than CC (Stage I a23,462; Stage 
II a35,059; Stage III a48,186; Stage IV a31,774). Cost estimates were most sensitive 
to recurrence rates and prescribing of the biologic agents bevacizumab and cetuximab. 
CONCLUSIONS: This study demonstrates how costs of managing cancer can be 
estimated using existing data from national and local databases. The ﬁndings illustrate 
the major impact that the new biologic agents have on the cost of cancer care. They 
also highlight the potential to reduce health care resource utilisation by implementing 
strategies to detect colorectal cancer at earlier stages.
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OBJECTIVES: A cross-sectional retrospective, prevalence-based study was designed 
to measure costs and QoL associated with MM management at different disease phases 
in a societal perspective. METHODS: A snapshot questionnaire was administered to 
236 subjects in 5 Italian hematological centers. Health-related QoL was measured 
using the EORTC QLQ-C30 and its MM speciﬁc module MY24, administered to 199 
patients at enrolment). Four disease-phases were considered in a distribution that 
reﬂects real clinical practice: asymptomatic, “watch-and-wait” (16%); symptomatic, 
receiving an autotransplant (12%); symptomatic, receiving drugs (45%); and plateau/
remission (including best supportive care) (27%). Costs were identiﬁed over 1 year 
of disease management with regard to: drugs, visits, laboratory tests, hospital admis-
sions, support devices, home assistance, travel, and reduced productivity of patients 
and caregivers. Costs for working days lost were derived according to the human 
capital method. RESULTS: The average costs per subject per year were a20,695 while 
direct health care costs were a16,717 and direct non-health care costs were a447; 
indirect costs (productivity loss) were a3,531 per subject per year. The average direct 
health care costs per subject per year were: a660; a53,020; a18,892; a6,319 for 
asymptomatic, autotransplanted, receiving drugs and plateau/remission respectively. 
The groups with the highest resource utilization were the autotransplanted and those 
receiving drugs. Regarding QoL, our sample of 199 patients recorded a 60.93 Global 
Health Score in QLQ-C30 (asymptomatic: 71.05; autotransplanted: 57.41; receiving 
drugs: 49.25; Plateau/remission: 72.02). CONCLUSIONS: The main resource utiliza-
tion comes from direct medical costs. MM treatment strategy has changed dramati-
cally in the past years. In particular, transplant and pharmacological treatments 
represent the most relevant costs, although counterbalanced by the highly increased 
clinical outcomes reported in literature (Kumar,Blood,2007). The QoL analysis 
showed the impact of maintaining patients in the plateau/remission phase, which 
ensures that their QoL and particularly the global health score is comparable with 
asymptomatic.
PCN50
HOSPITALISATIONS FOR HEAD AND NECK CANCERS IN FRANCE
Lacau St Guily J1, Borget I2, Vainchtock A3, Rémy V4
1Hôpital Tenon, Paris, France, 2Institut Gustave Roussy, Villejuif, France, 3HEVA, Lyon, France, 
4Sanoﬁ Pasteur MSD, Lyon, France
OBJECTIVES: With 16,005 new cases and 5,406 related deaths in 2005, France is 
particularly concerned by Head and Neck (H&N) cancers. In addition to tobacco and 
alcohol, Human Papillomavirus (HPV) has been reported as a risk factor for H&N 
cancers. The literature on the burden of these cancers in Europe is scarce. This study 
was performed to assess the medical and economical burden of hospitalisations for 
H&N cancers in France. METHODS: The French national hospital database (PMSI), 
in which admissions to public and private hospitals are recorded, was retrospectively 
analysed to assess the annual number of patients hospitalised for H&N cancers and 
associated hospital costs from the health care payer perspective. ICD-10 codes (16 
codes classiﬁed as oral cavity, pharynx, salivary glands, larynx) were used to extract 
admissions for these cancers. Hospital stays, chemotherapy and radiotherapy sessions 
were extracted to assess patients’ management. Costs of admissions were obtained 
from French ofﬁcial tariffs. RESULTS: In 2007, there were 35,069 patients hospital-
ised for H&N cancers, of whom 81% were men, corresponding to 60,200 hospital 
stays and 242,935 sessions of chemo- or radio-therapy. Pharynx cancer was the most 
frequent (49% of patients), followed by oral cavity cancer (37% of patients). The 
peak of frequency was observed in the 55–59 years age group. Patients were mainly 
treated in medicine (47%) and surgery (23%) units. Mean annual cost per patient 
ranged from a3,285 to a8,924, leading to a total hospital cost of a275 millions in 
2007. CONCLUSIONS: The hospital burden of H&N cancers is considerable. Fur-
thermore, these costs are underestimated since radiotherapy sessions performed in 
the private sector as well as expensive drugs were not available from the PMSI. The 
